McKesson (NYSE:MCK) Price Target Cut to $1,000.00 by Analysts at UBS Group

McKesson (NYSE:MCK) had its price target lowered by UBS Group from $1,012.00 to $1,000.00 in a research report released on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also recently commented on the stock. TD Cowen raised their price target on shares of McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a report on Thursday, February 5th. Raymond James Financial set a $970.00 price target on shares of McKesson in a report on Thursday, March 5th. Mizuho raised their price target on shares of McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a report on Thursday, February 5th. Leerink Partners restated an “outperform” rating and issued a $1,085.00 price target on shares of McKesson in a report on Thursday, March 5th. Finally, Evercore restated an “outperform” rating on shares of McKesson in a report on Thursday, March 5th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $972.27.

McKesson Stock Down 1.6%

MCK opened at $828.94 on Wednesday. McKesson has a twelve month low of $637.00 and a twelve month high of $999.00. The company has a fifty day moving average of $907.82 and a 200-day moving average of $856.80. The stock has a market cap of $101.54 billion, a PE ratio of 23.84, a price-to-earnings-growth ratio of 1.22 and a beta of 0.42.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping the consensus estimate of $9.19 by $0.15. The company had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. McKesson’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the prior year, the company posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Sell-side analysts anticipate that McKesson will post 39.02 EPS for the current fiscal year.

McKesson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, June 1st. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

Insider Buying and Selling at McKesson

In other news, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total transaction of $179,550.00. Following the completion of the transaction, the executive vice president directly owned 2,989 shares in the company, valued at $2,824,605. This trade represents a 5.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of McKesson stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $955.00, for a total transaction of $313,240.00. The SEC filing for this sale provides additional information. Insiders have sold 3,592 shares of company stock valued at $3,518,555 over the last three months. Corporate insiders own 0.08% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. GGM Financials LLC acquired a new position in shares of McKesson during the third quarter valued at about $25,000. University of Texas Texas AM Investment Management Co. acquired a new position in shares of McKesson during the fourth quarter valued at about $25,000. Swiss RE Ltd. acquired a new position in shares of McKesson during the fourth quarter valued at about $26,000. State of Wyoming acquired a new position in shares of McKesson during the second quarter valued at about $29,000. Finally, Hopwood Financial Services Inc. acquired a new position in shares of McKesson during the third quarter valued at about $31,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Apollo agreed to buy a minority stake in McKesson’s medical‑surgical solutions business for $1.25 billion, which monetizes a portion of the business, provides cash proceeds and signals third‑party investor interest in the asset. Apollo to acquire minority stake in McKesson’s medical-surgical solutions business for $1.25bn
• Positive Sentiment: McKesson’s board declared a quarterly dividend of $0.82 per share (payable July 1; record/ex‑div June 1), confirming steady cash return policy—modest yield but supportive for income‑oriented holders. McKesson Corporation Declares Quarterly Dividend
• Positive Sentiment: Analysis pieces highlight multi‑year earnings and EPS growth that underpin McKesson’s long‑term thesis as a compounding business, helping longer‑term investor conviction. Is McKesson Stock Still A High-Conviction Compounder?
• Neutral Sentiment: UBS lowered its price target from $1,012 to $1,000 but retained a Buy rating — still implying sizable upside from current levels, though the trim may temper upside expectations. UBS price target update
• Neutral Sentiment: Market attention is focused on McKesson’s Q4 FY2026 earnings due May 7; analysts expect double‑digit profit growth, making the report a near‑term catalyst that could swing sentiment either way. McKesson Earnings Preview: What to Expect
• Negative Sentiment: Recent coverage noted a more meaningful intraday/short‑term price drop relative to the broader market, which may reflect profit‑taking after recent gains and sensitivity to analyst commentary and near‑term catalysts. McKesson sees a more significant dip than broader market

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.